EVALUATION OF CLINICAL DATAS AND TREATMENT RESULTS OF PATIENTS WITH NON-HODGKIN LYMPHOMA

We studied the clinical and pathological data, staging, treatment and survival of patients with high-grade non-Hodgkin's lymphoma. We studied 26 high-grade non-Hodgkin's lymphoma patients who were followed by oncology outpatient clinic of the internal medicine clinic between the years 1997-2002. Median follow-up was 22 months. Median age was 60.5 (15-79) years. Ten (38.5%) patients were stage I, 10 (38.5%) were stage II, 3 (11.5%) were stage III, 3 (11.5%) were stage IV. Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) regimen was applied to the patients. In addition to CHOP chemotherapy, radiotherapy was applied for 14 (53.8%) cases. After the treatment, objective response was observed in 19 (73.1%) cases. For 7 patients who did not respond or who showed progression, second line chemotherapy was applied. In the follow up, 8 (38.8%) cases were died. Eighteen (69.2%) patients are still followed up. The median disease-free survival is 43 months. Three years disease free survival rate is 63.1%. Median overall survival is 52 months. Three-year overall survival rate is 66.4%. When the cases were classified according to IPI (International Prognostic Index), there was a significant relationship between disease-free survival and overall survival rates (p=0.002, p=0.003, long-rank test). The data obtained from patients that were diagnosed and followed up, as high-grade lymphoma in our hospital is similar to the data in the existing literature.

HODGKÝN DIÞI LENFOMALI HASTALARIN KLÝNÝK ÖZELLÝKLERÝNÝN VE TEDAVÝ SONUÇLARININ DEÐERLENDÝRÝLMESÝ

Çalýþmamýzda hastanemizde izlenen "high grade" Hodgkin dýþý lenfoma (HDL) hastalarýnýn klinik ve patolojik özelliklerini, tedavi sonuçlarýný ve saðkalým sürelerini deðerlendirdik. 1997-2000 yýllan arasýnda onkoloji polikliniðimizde izlenen 26 (kadýn/erkek: 16/10) HDL hastasýný retrospektif olarak deðerlendirdik. Median izlem süresi 22 ay idi. Median yaþ, 60.5 (15-79) yýldý. Hastalarýmýzýn 10'u (%38.5) evre I, 10'u (%38.5) evre II, 3'ü (%11.5) evre III, 3'ü (%11.5) ise evre IV idi. Hastalara 6 kür CHOP (siklofosfamid, adriyamisin, vinkristin, prednizolon) kemoterapisi uygulandý. 14 (%53.8) hastaya ek olarak radyoterapi (RT) verildi. Tedavi sonrasý objektif yanýt oraný 73.1 (19 olgu) idi. Yanýtsýz veya daha sonrasýnda progresyon gösteren 7 hastaya 2. seri kemoterapi (KT) uygulandý. Ýzlem süresince 8 (%38.8) hasta öldü. 18 (%69.2) hasta izlenmeye devam edilmektedir. Survi analizinde median hastalýksýz yaþam süresi 43 ay, 3 yýllýk hastalýksýz yaþam % 60.1, median genel sað kalým süresi 52 ay, 3 yýllýk genel saðkalým ise %66.4 olarak bulundu. Hastalar "International Prognostic Index" (IPI)'e göre sýnýflandýrýldýðýnda, IPI ile hastalýksýz saðkalým ve genel saðkalým arasýnda istatistiksel olarak anlamlý iliþki saptandý (p=0.002, p=0.003, log-rank test). HDL tanýsýyla takip edilen hastalarýn 3 yýllýk verileri deðerlendirildiðinde literatürle uyumlu bulundu.